Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

Inclusion Criteria:

1. Subjects with confirmed SARS-CoV-2 infection
2. Be ≥ 18 years old and ≤90 years old
3. Acute respiratory distress syndrome assessed by a modified Sequential Organ FailureAssessment score of at least 2 points
4. At least one additional organ dysfunction assessed by a modified Sequential OrganFailure Assessment score of at least 1 point
5. Written or electronic consent of the subjects who are legally competent and have thecapacity to give consent

Exclusion Criteria:

1. Subject is currently participating in another clinical investigation
2. Pregnant or nursing subjects and those who plan pregnancy during the clinicalinvestigation follow-up period
3. Presence of comorbid conditions, or other medical, social, or psychological conditionsthat, in the investigator's opinion, could limit the subject's ability to participatein the clinical investigation or to comply with follow-up requirements, or impact thescientific soundness of the clinical investigation results
4. Have Child-Pugh Class C cirrhosis
5. Have platelet count <30.000/uL
6. Contraindications for heparin sodium for injection
7. Subjects demonstrating any contraindication for this treatment as described in the IFU
8. Subjects with known allergy of polyethylene and copolyester
9. Subjects with hospital-acquired SARS-CoV-2 infections
10. Subject is held in an institution by court or official order
11. Subject is dependent on the sponsor or investigator so that consent can no longer beconsidered voluntary